Business Context and Reporting Period
Company: Techne Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended December 31, 1999
Business Overview: The Company operates through two primary subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) in Minneapolis, MN, and R&D Systems Europe Ltd. in Abingdon, England. R&D Systems comprises Biotechnology (cytokines, antibodies, assay kits) and Hematology (controls and calibrators) divisions. The Company also holds an equity interest in ChemoCentryx, Inc. (CCX).
Key Financial Metrics
| Metric | Quarter Ended 12/31/99 | Six Months Ended 12/31/99 |
|---|---|---|
| Net Sales | $25,126,839 | $49,747,892 |
| Gross Margin | $18,149,107 (72.2%) | $35,773,390 (71.9%) |
| Net Earnings | $5,564,063 | $10,412,302 |
| Diluted EPS | $0.26 | $0.50 |
| Cash & Equivalents | $18,695,132 | $18,695,132 (Ending Balance) |
| Short-term Investments | $20,621,718 | $20,621,718 (Ending Balance) |
| Total Debt (Current + Long-term) | $20,148,296 | $20,148,296 (Ending Balance) |
| Operating Cash Flow (6mo) | N/A | $17,140,433 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17% ($3.66M) for the quarter and 16% ($6.95M) for the six months compared to the prior year periods. Growth was driven by a $2.5M increase in protein/antibody sales and a $0.5M increase in immunoassay kit sales for the quarter.
- Profitability: Net earnings rose 55% for the quarter and 46% for the six months. Earnings before taxes increased due to higher divisional earnings and reduced losses from the CCX investment, partially offset by new mortgage interest expense.
- Margins: Gross margins improved to 72.2% for the quarter (from 71.0%) and 71.9% for the six months (from 70.0%). Biotechnology margins increased due to volume and reduced rent expense following the facility purchase. R&D Europe margins declined slightly due to foreign exchange rates.
- Capital Structure: The Company incurred significant debt to finance the purchase of its Minneapolis facility. Long-term debt increased from $0 to $19.36M, and current portion of long-term debt is $0.79M. Fixed assets increased significantly from $15.1M to $42.4M.
- Investing Activities: Net cash used in investing activities was $32.4M for the six months, primarily due to $24.7M in additions to fixed assets (including the building purchase) and a net increase in short-term investments.
Guidance, Outlook, and Risks
- Capital Expenditures: Remaining capital additions for fiscal 2000 are expected to cost approximately $5.7 million, financed by available funds and operating cash flow.
- Liquidity: Management believes current funds, operating cash flow, and short-term investment maturities are sufficient to meet future requirements. An unsecured line of credit of $750,000 is available but currently unused.
- Stock Repurchases: The Board has authorized the repurchase of up to $10 million of common stock. As of February 7, 2000, $8.75 million worth of shares had been repurchased.
- Risks: Key risks include the acceptance of new products, price competition in cytokine research, retention of hematology OEM business, and the success of R&D efforts. The Company is also exposed to foreign currency fluctuations, though historically the impact has been immaterial.
- Y2K Status: No significant Y2K problems have been experienced to date.
Investor Verification Checklist
- Debt Service: Verify the impact of the new $20.4M mortgage (7% fixed for 7 years) on future interest expenses and cash flow.
- Real Estate: Confirm the status of the option to purchase adjacent property (deposit paid, warrants issued) and potential future capital requirements.
- CCX Investment: Monitor the equity investment in ChemoCentryx, Inc., as the Company recognizes 100% of its losses despite limited cash consideration.
- Foreign Exchange: Assess the sensitivity of R&D Europe's margins to currency fluctuations, which recently caused a margin decline.
- Product Pipeline: Evaluate the timeline and commercial viability of the biotechnology and hematology products currently under development.